Sec Form 3/A Filing - Nextech V Oncology S.C.S., SICAV-SIF @ PMV Pharmaceuticals, Inc. - 2020-09-24

FORM 3/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Nextech V Oncology S.C.S., SICAV-SIF 2. Issuer Name and Ticker or Trading Symbol PMV Pharmaceuticals, Inc. [ PMVP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 8 RUE LOU HEMMER 3. Date of Earliest Transaction (MM/DD/YY) 09/24/2020 (Street) SENNINGERBERG, LUXEMBOURG, N4L-1748 4. If Amendment, Date Original Filed (MM/DD/YY) 09/24/2020 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series C Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 1,768,023 D ( 2 ) Series D Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 760,267 D ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Nextech V Oncology S.C.S., SICAV-SIF 8 RUE LOU HEMMER SENNINGERBERG, LUXEMBOURG, N4L-1748 X NEXTECH V GP S.A R.L. 8 RUE LOU HEMMER SENNINGERBERG, LUXEMBOURG, N4N4 L-1748 X Bleyer Dalia 8 RUE LOU HEMMER SENNINGERBERG, LUXEMBOURG, N4N4 L-1748 X Lips Thomas 8 RUE LOU HEMMER SENNINGERBERG, LUXEMBOURG, N4N4 L-1748 X Detournay Philippe 8 RUE LOU HEMMER SENNINGERBERG, LUXEMBOURG, N4N4 L-1748 X Signatures Nextech V Oncology S.C.S., SICAV-SIF, By: /s/ Dalia Bleyer and /s/ Philippe Detournay, Managers of Nextech V GP S.a r.l., its General Partner 09/29/2020 Signature of Reporting Person Date NEXTECH V GP S.A R.L., By: /s/ Dalia Bleyer and /s/ Philippe Detournay, Managers 09/29/2020 Signature of Reporting Person Date /s/ Dalia Bleyer 09/29/2020 Signature of Reporting Person Date /s/ Thomas Lips 09/29/2020 Signature of Reporting Person Date /s/ Philippe Detournay 09/29/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. ( 2 )The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any.

Remarks: This amendment is being filed solely to add additional Reporting Persons to the Form 3 originally filed by Nextech V Oncology S.C.S., SICAV-SIF on September 24, 2020. Aside from the addition of such Reporting Persons, the content of the original Form 3 is unchanged hereby.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.